IndustryCompany release
Jasper Therapeutics reports 68.94% of warrants tendered in $0.324-per-warrant buyback offer
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 09 Nov 2026
Jasper Therapeutics (Nasdaq: JSPR) announced on November 9, 2026 the results of its cash tender offer for warrants issued in its September 2025 underwritten public offering, which expired November 7, 2026. Holders tendered 8,510,658 warrants, about 68.94% of those outstanding, and the company expects to pay roughly $2.76 million at $0.324 per warrant. The offer was made under a Schedule TO filed with the SEC on October 7, 2026.
Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IM Cannabis Corp. (IMCC) · Fri 13 Nov 2026
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
Helus Pharma Inc. (HELP) · Fri 13 Nov 2026
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IM Cannabis Corp. (IMCC) · Fri 13 Nov 2026
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
🇺🇸 DataMeds AI, Inc. (MEDS) · Fri 13 Nov 2026
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
🇺🇸 Xenetic Biosciences, Inc. (XBIO) · Fri 13 Nov 2026
IndustryCompany releaseLifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partners
🇺🇸 Lifeward Ltd. (LFWD) · Fri 13 Nov 2026